Removing T-cell epitopes with computational protein design

Proceedings of the National Academy of Sciences of the United States of America

Volumn 111, Issue 23, 2014, Pages 8577-8582

  King, Chris ^a   Garza, Esteban N ^b   Mazor, Ronit ^c   Linehan, Jonathan L ^d   Pastan, Ira ^c   Pepper, Marion ^b   Baker, David ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

^d NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

Biotherapeutics; Deimmunization; Immunotoxin; Machine learning; Rosetta

Indexed keywords

EPITOPE; PSEUDOMONAS EXOTOXIN;

AMINO ACID SEQUENCE; ARTICLE; COMPUTATIONAL PROTEIN DESIGN; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN PROCESSING; T LYMPHOCYTE;

BIOTHERAPEUTICS; DEIMMUNIZATION; IMMUNOTOXIN; MACHINE LEARNING; ROSETTA;

ADP RIBOSE TRANSFERASES; ANIMALS; BACTERIAL TOXINS; CELL LINE, TUMOR; COMPUTER-AIDED DESIGN; EPITOPES, T-LYMPHOCYTE; EXOTOXINS; FLOW CYTOMETRY; GREEN FLUORESCENT PROTEINS; HLA ANTIGENS; HUMANS; IMMUNIZATION; IMMUNOTOXINS; MICE; MICE, INBRED C57BL; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; PROTEIN ENGINEERING; PROTEIN STRUCTURE, TERTIARY; PROTEINS; SEQUENCE HOMOLOGY, AMINO ACID; SPECTROMETRY, FLUORESCENCE; SUPPORT VECTOR MACHINES; VIRULENCE FACTORS;

EID: 84902198472     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1321126111     Document Type: Article

References (34)

1. Zubler RH (2001) Naive and Memory B Cells in T-Cell-Dependent and T-Independent Responses. Springer Seminars in Immunopathology (Springer, Berlin), pp 405-419.
2. Goldenberg MM (1999) Trastuzumab, a recombinant DNA-derived humanized monoclonal antibody, a novel agent for the treatment of metastatic breast cancer. Clin Ther 21(2):309-318.
3. Harding FA, et al. (2005) A beta-lactamase with reduced immunogenicity for the targeted delivery of chemotherapeutics using antibody-directed enzyme prodrug therapy. Mol Cancer Ther 4(11):1791-1800. (Pubitemid 41685314)
4. Tangri S, et al. (2005) Rationally engineered therapeutic proteins with reduced immunogenicity. J Immunol 174(6):3187-3196. (Pubitemid 40354020)
5. Vita R, et al. (2010) The immune epitope database 2.0. Nucleic Acids Res 38(Database issue):D854-D862.
6. Nielsen M, Lund O, Buus S, Lundegaard C (2010) MHC class II epitope predictive algorithms. Immunology 130(3):319-328.
7. Parker AS, Griswold KE, Bailey-Kellogg C (2011) Optimization of therapeutic proteins to delete T-cell epitopes while maintaining beneficial residue interactions. J Bioinform Comput Biol 9(2):207-229.
8. Parker AS, Zheng W, Griswold KE, Bailey-Kellogg C (2010) Optimization algorithms for functional deimmunization of therapeutic proteins. BMC Bioinformatics 11(1):180.
9. Choi Y, Griswold KE, Bailey-Kellogg C (2013) Structure-based redesign of proteins for minimal T-cell epitope content. J Comput Chem 34(10):879-891.
10. Nivón LG, Bjelic S, King C, Baker D (2014) Automating human intuition for protein design. Proteins 82(5):858-866.
11. Wang P, et al. (2008) Immune epitope database: MHC-II binding dataset. Available at http://tools.iedb.org/mhcii/download/. Accessed February 14, 2013.
12. Flicek P, et al. (2012) Ensembl 2012. Nucleic Acids Res 40(Database issue):D84-D90.
13. Nielsen M, Justesen S, Lund O, Lundegaard C, Buus S (2010) NetMHCIIpan-2.0 - Improved pan-specific HLA-DR predictions using a novel concurrent alignment and weight optimization training procedure. Immunome Res 6(1):9.
14. Singh H, Raghava GPS (2001) ProPred: Prediction of HLA-DR binding sites. Bioinformatics 17(12):1236-1237. (Pubitemid 33735355)
15. Southwood S, et al. (1998) Several common HLA-DR types share largely overlapping peptide binding repertoires. J Immunol 160(7):3363-3373. (Pubitemid 28164729)
16. Cantor JR, et al. (2011) Therapeutic enzyme deimmunization by combinatorial T-cell epitope removal using neutral drift. Proc Natl Acad Sci USA 108(4):1272-1277.
17. Pedelacq JD, Cabantous S, Tran T, Terwilliger TC, Waldo GS (2006) Engineering and characterization of a superfolder green fluorescent protein. Nat Biotechnol 24(1):79-88. (Pubitemid 43083170)
18. Brazelton TR, Blau HM (2005) Optimizing techniques for tracking transplanted stem cells in vivo. Stem Cells 23(9):1251-1265. (Pubitemid 41504913)
19. Persons DA, et al. (1998) Use of the green fluorescent protein as a marker to identify and track genetically modified hematopoietic cells. Nat Med 4(10):1201-1205. (Pubitemid 28468837)
20. FitzGerald DJ, Wayne AS, Kreitman RJ, Pastan I (2011) Treatment of hematologic malignancies with immunotoxins and antibody-drug conjugates. Cancer Res 71(20):6300-6309.
21. Kreitman RJ, et al. (2012) Phase I trial of anti-CD22 recombinant immunotoxin moxetumomab pasudotox (CAT-8015 or HA22) in patients with hairy cell leukemia. J Clin Oncol 30(15):1822-1828.
22. Wayne AS, et al. (2011) A novel anti-CD22 immunotoxin, moxetumomab pasudotox: Phase I study in pediatric acute lymphoblastic leukemia (ALL). ASH Annual Meeting Abstracts 118(21):248.
23. Hassan R, et al. (2007) Phase I study of SS1P, a recombinant anti-mesothelin immunotoxin given as a bolus I.V. infusion to patients with mesothelin-expressing mesothelioma, ovarian, and pancreatic cancers. Clin Cancer Res 13(17):5144-5149. (Pubitemid 47502082)
24. Mazor R, et al. (2012) Identification and elimination of an immunodominant T-cell epitope in recombinant immunotoxins based on Pseudomonas exotoxin A. Proc Natl Acad Sci USA 109(51):E3597-E3603.
25. De Groot AS, Terry F, Cousens L, Martin W (2013) Beyond humanization and deimmunization: Tolerization as a method for reducing the immunogenicity of biologics. Expert Rev Clin Pharmacol 6(6):651- 662.
26. Baker M, Carr F (2010) Pre-clinical considerations in the assessment of immunogenicity for protein therapeutics. Curr Drug Saf 5(4):308-313.
27. Greenbaum JA, et al. (2007) Towards a consensus on datasets and evaluation metrics for developing B-cell epitope prediction tools. J Mol Recognit 20(2):75-82. (Pubitemid 46761248)
28. Nagata S, Pastan I (2009) Removal of B cell epitopes as a practical approach for reducing the immunogenicity of foreign protein-based therapeutics. Adv Drug Deliv Rev 61(11):977-985.
29. Onda M, et al. (2008) An immunotoxin with greatly reduced immunogenicity by identification and removal of B cell epitopes. Proc Natl Acad Sci USA 105(32):11311-11316.
30. Hammer J, et al. (1993) Promiscuous and allele-specific anchors in HLA-DR-binding peptides. Cell 74(1):197-203. (Pubitemid 23219890)
31. Yanover C, Bradley P (2011) Large-scale characterization of peptide-MHC binding landscapes with structural simulations. Proc Natl Acad Sci USA 108(17):6981-6986.
32. Fleishman SJ, et al. (2011) RosettaScripts: A scripting language interface to the Rosetta macromolecular modeling suite. PLoS ONE 6(6):e20161.
33. + T cell frequency varies for different epitopes and predicts repertoire diversity and response magnitude. Immunity 27(2):203-213.
34. Pastan I, Beers R, Bera TK (2004) Recombinant Immunotoxins in the Treatment of Cancer. Antibody Engineering (Springer, Berlin), pp 503-518.